Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.92 USD
-0.03 (-2.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.92 0.00 (-0.42%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Oncolytics Biotech Inc. [ONCY]
Reports for Purchase
Showing records 1 - 20 ( 145 total )
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
"We Are the Purple Dye": Clear Registrational Path Forward With Oncolytic Virus Lead in Breast and Pancreas; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Phase 3 Study Starts With Pelareorep in Breast and Pancreatic Cancers on Track in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pelareorep Phase 3 Trials in Breast and Pancreatic Cancers to Start in 2024; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
GOBLET Expands to Evaluate Lead Program Pelareorep in Combination Setting For Advanced Anal Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Collaboration Discussions Gaining Momentum on Lead Program Pelareorep; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Start in Pancreatic Cancer Expected in Mid-2024; Provides Guidance For 2024 in Line With Expectations; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Pelareorep Awakens Expansion of Antitumor T Cells in Breast Cancer Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Pivoting Clinical Development Strategy For Pelareorep in Pancreatic Cancer; Moderating Price Target to $5; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
GOBLET Meets Success Criteria For Efficacy in Anal Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Lead Oncolytic Agent Pelareorep Progressing in Multiple Pancreatic Cancer Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Signals of Durable Clinical Benefit With Pelareorep in Pancreatic Cancer Emerge From Phase 1/2 Update at ESMO; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Lead Oncolytic Agent Pelareorep Progressing in Pancreatic Cancer Pivotal Platform Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Lead Program Pelareorep Expected to Advance to Phase 3 in Pancreatic Cancer Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Takeaways: Lead Candidate Pelareorep Expected to Advance to Registrational Program in Breast Cancer; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
ASCO Update; Pelareorep Demonstrates Potential in Metastatic Breast Cancer; KOL Event Expected June 5; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Pipeline Progressing on Track; Phase 2 Breast Cancer, Preclinical CAR T Combination Data Expected at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Lead Oncolytic Virus Program Pelareorep on Track for Several Data Updates in 1H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
Lead Program Pelareorep Continues to Shine; KOL Event Highlights Compelling Pancreatic Cancer Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Oncolytics Biotech Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Earnings; Lead Oncolytic Virus Program Pelareorep Progressing; Multiple Updates on Track for 2H22 and 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P